No Data
Medicago: 2024 Semi-Annual Report
Medicago: 2024 Semi-Annual Report Summary
PharmacyEasy(300937.SZ): The net income in the first half of the year was 12.0957 million yuan, a year-on-year decrease of 74.11%.
On August 27, GeLongHui announced its semi-annual report for 2024. The revenue for the reporting period was 2.225 billion yuan, a year-on-year increase of 0.93%; the net profit attributable to the shareholders of the listed company was 12.0957 million yuan, a year-on-year decrease of 74.11%; the net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 8.4812 million yuan, a year-on-year decrease of 80.80%; and the basic earnings per share was 0.13 yuan.
Yaeyigou (300937.SZ): Sales of Simcereglasin have not yet been conducted.
Yiyaigou (300937.SZ) stated on the investor interaction platform on August 9 that, currently, the company operates over 23,000 pharmaceutical products, covering multiple categories such as western medicine, chinese patent medicine, traditional chinese medicine extracts and herbs, food and health products, medical instruments, non-pharmaceutical products, and others. The sales of Simcere gluotide have not yet been conducted.
PharmEasy (300937.SZ): Has completed the construction of a C-end full-domain operation team and system, and is fully committed to cultivating the company's second growth curve.
On July 25th, Guosen Securities reported that the investor relations activity record of Yaoyigou (300937.SZ) showed that the company's core competitiveness mainly lies in: Yaoyigou has innovative internet and big data technology; an ecological system of full-chain pharmaceutical services covering the out-of-hospital market; rich variety of resources and upstream channel advantages; comprehensive and multilevel pharmaceutical distribution and empowering service system; industry-leading layout of the entire C-end, system construction, diversified team, and leading e-commerce development. The company has accumulated leading technological strength, basic infrastructure capabilities, terminal store coverage capabilities, and full-category products in the first growth curve that are ahead of the industry.
Yaoyigou (300937.SZ): Currently promoting the new retail model of "AI membership".
On July 25th, Gelonhui reported that Yaoyigou (300937.SZ) disclosed an investor relations activity record table which showed that in the offline retail sector, the company's key exploration direction was to treat retail stores as traffic entrances, extending diversified business services and professional chronic disease management services. The company is currently promoting the 'AI Member' new retail model, and by combining marketing and benefiting patients, it is driving the sales of cross-industry products without destroying the pharmaceutical supply chain system. In addition, the company has also formed a chronic disease management team to expand chronic disease management services. Through these two points, the future sales model will transition from treating disease to preventing disease.
No Data
No Data